Agustín Lage Dávila

SUMMARY OF CURRICULUM VITAE 

 Dr. Agustín Lage                                                                                                      

Born:      22 March, 1949, Havana, Cuba

Current Position:  Director of the Center of Molecular Immunology (since 1991).

                                               P.O.Box 16040, Havana 11600, Cuba

                                               Teleph.: 537-214335  Fax: 537-335049

                                               E.mail: Lage@cim.sld.cu

 Previous Positions:        

1985-1991           Deputy Director for Research at the National Institute of Oncology and Radiobiology, Havana, Cuba.

1979-1985               Head of the Biochemistry Dept. at The National Institute of Oncology and Radiobiology, Havana, Cuba.

1972-1985               Scientific researcher (National Institute of Oncology and Radiobiology)

 Academic Studies:             

1972                        Graduated of Doctor in Medicine at Havana University.

1972-1974               Specialization in Biochemistry at The National Center of Scientific Research, Havana, Cuba.

1976-1978               Post-graduated studies at Pasteur Institute in Paris, France, under the direction of Prof. Luc Montagnier.

1979                        Ph.D. Thesis: Membrane changes associated with malignant transformation.

Academic Degree:   

 - Ph.D. (1979)

 - Professor of the Institute of Medical Sciences, Havana, Cuba (since 1991).

 - Merit Member of  the Cuban Academy of Sciences

 

Scientific Committee Membership:

Member of the Editorial Board of the Journal "Biotecnologia Aplicada" (Applied Biotechnology).

Member of the Advisory Committee of Health Research of Pan American Health Organization (1992-1998)

 

Political Membership: Member of the Cuban Parliament (National Assembly of the Popular Power). (1993-current)

 

Languages: Spanish, English and French.

 

Scientific Articles: Published in English:              66

                           Published in Spanish:             79

                            Total:                                154

 Fields of Research:

  1. Membrane proteins and functions associated with malignant transformation (1972-1978).
  2. Mechanisms of control of cell proliferation (1979-1985).
  3. Biochemical factors associated with prognosis in human breast cancer (1979-1985).
  4. Monoclonal antibodies for the treatment of cancer (1986-actual).
  5. Cáncer vaccines (1994-currently).

 

 MOST RECENT PUBLISHED PAPERS

  1.  Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. Gonzalez G, Crombet T, Lage A. Curr Cancer Drug Targets. 2010 Jan 1;11(1):103-10.
  2. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. Rodríguez PC, Rodríguez G, González G, Lage A. MEDICC Rev. 2010 Winter;12(1):17-23. Review.
  3. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Montero E, Valdes M, Avellanet J, Lopez A, Perez R, Lage A. Vaccine. 2009 Apr 6;27(16):2230-9.
  4. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, Mazorra Z, Fleites G, González M, Wilkinson B, González G, Lage A. J Immunother. 2009 Jan;32(1):92-9.
  5. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Rodriguez PC, Gonzalez I, Gonzalez A, Avellanet J, Lopez A, Perez R, Lage A, Montero E. Vaccine. 2008 Aug 26;26(36):4647-54.
  6. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. Clin Cancer Res. 2008 Feb 1;14(3):840-6.
  7. Connecting immunology research to public health: Cuban biotechnology. Lage A. Nat Immunol. 2008 Feb;9(2):109-12. Erratum in: Nat Immunol. 2008 Mar;9(3):329.
  8. How regulatory CD25+CD4+ T cells impinge on tumor immunobiology: the differential response of tumors to therapies. Leon K, Garcia K, Carneiro J, Lage A. J Immunol. 2007 Nov 1;179(9):5659-68.
  9. Interleukin-2 mastering regulation in cancer and autoimmunity. Montero E, Alonso L, Perez R, Lage A. Ann N Y Acad Sci. 2007 Jun;1107:239-50.
  10. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. González G, Crombet T, Neninger E, Viada C, Lage A. Hum Vaccin. 2007 Jan-Feb;3(1):8-13. Epub 2007 Jan 22.
  11. On the cross-fertilization between biotechnology and immunology: current situation in Cuba. Lage A. Vaccine. 2006 Apr 12;24 Suppl 2:S2-3-6. Review.
  12. 12.              Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A. Cancer Biol Ther. 2006 Apr;5(4):375-9. Epub 2006 Apr 19.